Holen Sie sich die Stockscreener-App
23.72
3.42%
-0.84
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences Inc (CSTL) Stock Down 3.4% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Castle Biosciences (CSTL) to Release Q2 Financial Results on Jul - GuruFocus
Castle Biosciences sets July 30 webcast for Q2 results - Stock Titan
Castle Biosciences updates its melanoma testing strategy as diagnostics demand grows - ad-hoc-news.de
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - AOL.com
Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan - Stock Titan
Form 4 Castle Biosciences Inc For: 6 July By Investing.com - Investing.com Nigeria
Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock - Investing.com
Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan - Stock Titan
The Technical Signals Behind (CSTL) That Institutions Follow - Stock Traders Daily
Q1 2026 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Enterprise value to revenue forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Castle Biosciences Inc (CSTL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 144 Castle Biosciences For: 1 July By Investing.com - Investing.com Canada
Maetzold family Rule 144 sales reported for CSTL (CSTL) — multiple small lots - Stock Titan
Castle Biosciences (CSTL) Surges 6% as Bullish Momentum BuildsMerger Arbitrage - dars.gov.et
Castle Biosciences updates its melanoma test data, shares in biotech focus - AD HOC NEWS
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Yahoo Finance
Castle Biosciences (CSTL) Study Highlights Advancements in Melan - GuruFocus
Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool - Investing.com
Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - norfolkneradio.com
Roth Capital Initiates Castle Biosciences at Buy - Moomoo
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
CSTL Forecast — Price Target — Prediction for 2027 - TradingView
CSTL Initiated by Roth Capital -- Price Target Announced at $40. - GuruFocus
Price to earnings forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to EBITDA forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to revenue forward of Castle Biosciences, Inc. – TRADEGATE:086 - TradingView
Castle Biosciences (CSTL) Receives Buy Rating and $40 Target fro - GuruFocus
Enterprise value to EBIT forward of Castle Biosciences, Inc. – TRADEGATE:086 - TradingView
Castle Biosciences prioritizes people across patients, clinicians, and employees - Traders Union
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal - Sahm
Castle Biosciences Inc (CSTL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Castle Biosciences CFO receives Houston business award By Investing.com - Investing.com South Africa
Castle Biosciences celebrates Frank Stokes win at Houston Business Journal CFO Awards - Traders Union
Castle Biosciences CFO Frank Stokes Named Houston Business Journal CFO Awards Honoree - citybiz
Castle Biosciences' Chief Financial Officer Frank Stokes Named a - GuruFocus
Castle Biosciences CFO receives Houston business award - Investing.com
Castle Biosciences CFO Frank Stokes named among 22 Houston finance leaders - Stock Titan
CSTL Q1 2026 Earnings: Narrowly Exceeds EPS Estimates, Stock Edges HigherRetail Earnings Report - dars.gov.et
Castle Biosciences Inc (CSTL) Institutional Confidence - TradingKey
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Castle Biosciences (CSTL) COO sells 8,587 shares, retains over 127K - Stock Titan
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Castle Biosciences Inc (CSTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
0.29%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):